Beyond rarity: Building RWE strategies for the next generation of orphan drug markets

Rarity is no longer enough. As orphan drug markets become more crowded and payers challenge evidence, price, and durability claims with increasing scrutiny, manufacturers need to rethink how they prove value. This article explores how to use real-world evidence as a strategic access lever to help orphan assets defend unmet need, quantify comparative benefit, address long-term uncertainty, and differentiate in increasingly competitive rare disease markets.

The orphan drug landscape is shifting

The global orphan drug market now exceeds $200 billion and is projected to continue growing at a double-digit annual rate, significantly outpacing the broader pharmaceutical market. Gene therapies, precision biologics, and disease-modifying treatments have transformed rare diseases from a niche segment into a major revenue driver. But the…